HanchorBio Advances HCB101 Global Partnering Opportunities at BIO-Europe 2026
Expanding clinical evidence and macrophage-directed combination potential open new pathways for global collaboration.
TAIPEI, SHANGHAI, and SAN FRANCISCO — October 27, 2026 — HanchorBio, Inc. (TWSE: 7827), a global clinical-stage biotechnology company developing next-generation immunotherapies for oncology and immune-mediated diseases, today announced its participation in BIO-Europe 2026, taking place November 9–11 in Cologne, Germany.
Since BIO-Europe Spring, HanchorBio has achieved significant milestones, including its Taiwan Stock Exchange Innovation Board listing, expanding HCB101 clinical evidence, U.S. FDA feedback supporting a randomized registrational development strategy in second-line gastric cancer, U.S. IND clearance for HCB303, and strategic collaborations with InxMed and Aston Sci.
These advances position HanchorBio to pursue a broader opportunity: developing HCB101 as a potential macrophage-directed immunotherapy backbone while expanding global partnerships and the value of its FBDB™ platform.
HCB101: From Clinical Evidence to Global Franchise Potential
HCB101, HanchorBio’s lead engineered SIRPα–IgG4 Fc fusion protein, is designed to restore macrophage-mediated tumor clearance through CD47–SIRPα checkpoint blockade while reducing red blood cell binding.
In second-line gastric/gastroesophageal junction (GC/GEJ) cancer, an October 2026 clinical update reported a preliminary 50.0% objective response rate (11/22) and 100% disease control rate with HCB101 plus ramucirumab and paclitaxel. U.S. FDA feedback supported the proposed randomized Phase 2b dose-optimization lead-in followed by a confirmatory Phase 3 trial with overall survival as the primary endpoint.
Beyond gastric cancer, preliminary clinical observations across colorectal cancer (CRC), head and neck squamous cell carcinoma (HNSCC), and triple-negative breast cancer (TNBC), together with encouraging preclinical combination findings, support further investigation of HCB101 across complementary treatment approaches.
Approaches under consideration include tumor-targeting antibodies, antibody-drug conjugates (ADCs), PD-1/VEGF bispecifics, therapeutic cancer vaccines, and tumor microenvironment-modulating agents.
HanchorBio believes HCB101’s potential value extends beyond any single indication, with opportunities to build a broader immunotherapy program through scientifically validated combinations and global development partnerships.
From Scientific Innovation to Strategic Partnerships
HanchorBio is advancing a partner-enabled development strategy that combines HCB101’s macrophage-directed mechanism with complementary therapeutic technologies.
Recent collaborations with InxMed, involving FAK inhibition, and Aston Sci., involving therapeutic cancer vaccines, reflect the Company’s expanding approach to combination development.
At BIO-Europe, HanchorBio plans to continue ongoing scientific discussions and explore potential new collaborations focused on preclinical evaluation, clinical co-development, drug supply, joint research, and strategic licensing.
The objective is to translate complementary science into defined development programs, supported by appropriate experimental evidence, clinical strategies, and shared development capabilities.
FBDB™: Extending Innovation Beyond HCB101
HCB101 provides a clinical foundation for HanchorBio’s proprietary Fc-Based Designer Biologics (FBDB™) platform, which integrates Fc engineering and multifunctional molecular design to address complementary immune pathways.
The Company’s expanding pipeline includes:
- HCB303, a SIRPα × PD-L1 × TIGIT trispecific immunotherapy that received U.S. FDA IND clearance in October 2026.
- HCB206, a CD20 × SIRPα bispecific being developed for B-cell malignancies and autoimmune diseases, with planned oncology and autoimmune IND submissions subject to completion of the required development work.
- HCB301, a clinical-stage SIRPα × PD-L1 × TGFβ trispecific undergoing continued safety and development evaluation.
These programs demonstrate HanchorBio’s broader molecular engineering capabilities and provide additional opportunities for independent development and strategic partnerships.
About HanchorBio
HanchorBio Inc. (TWSE: 7827) is a global clinical-stage biotechnology company developing next-generation biologics for cancer and immune-mediated diseases through its proprietary FBDB™ platform. Powered by a multifunctional protein-engineering technology, its pipeline includes HCB101, HCB301, and HCB303. Operating across Taipei, the San Francisco Bay Area, and Shanghai, HanchorBio is committed to reimagining immunotherapy for patients worldwide.
Forward-Looking Statements
This press release contains forward-looking statements regarding HanchorBio’s investigational products, clinical and regulatory development plans, potential therapeutic applications, future partnerships, combination strategies, and platform opportunities. These statements are subject to scientific, clinical, regulatory, commercial, and operational risks and uncertainties. Preliminary clinical findings may not predict results in subsequent controlled studies, and proposed combinations or collaborations may not achieve their intended objectives. HanchorBio undertakes no obligation to update forward-looking statements except as required by applicable law.
HanchorBio Business Development Contact:
Email: [email protected]
Investor & Media Contact:
Email: [email protected]
漢康-KY於 BIO-Europe 2026 推進 HCB101 全球策略合作機會
持續累積的臨床證據與巨噬細胞導向聯合治療潛力，為全球合作開拓新契機
【台北、上海、舊金山，2026 年 10 月 27日】－全球臨床階段生技公司漢康-KY（TWSE：7827）致力於開發癌症及免疫介導疾病的下一代免疫療法，今日宣布將參加於 11 月 9 日至 11 日在德國科隆舉行的 BIO-Europe 2026 生技產業合作大會。
自今年 BIO-Europe 春季大會以來，漢康生技已達成多項重要里程碑，包括於臺灣證券交易所創新板掛牌上市、持續累積 HCB101 臨床證據、美國食品藥物管理局（FDA）針對二線胃癌隨機分組註冊性臨床開發策略提供支持性回饋、HCB303 獲得美國 FDA 新藥臨床試驗申請（IND）核准，以及與應世生物和 Aston Sci. 建立策略合作關係。
這些進展為漢康生技開拓更廣泛的發展機會奠定基礎，推動 HCB101 成為具潛力的巨噬細胞導向免疫治療骨幹，同時拓展全球合作夥伴關係，進一步提升 FBDB™ 平台的價值。
HCB101：從臨床證據邁向全球產品布局潛力
HCB101 為漢康生技主要開發中的工程化 SIRPα–IgG4 Fc 融合蛋白，旨在透過阻斷 CD47–SIRPα 免疫檢查點訊號，恢復巨噬細胞清除腫瘤的能力，同時降低與紅血球的結合。
在二線胃癌/胃食道交界部癌（GC/GEJ）方面，2026 年 10 月公布的臨床更新顯示，HCB101 聯合雷莫蘆單抗（ramucirumab）及紫杉醇（paclitaxel）的治療方案，初步客觀緩解率（ORR）達 50.0%（11/22），疾病控制率（DCR）達 100%。美國 FDA 的回饋支持公司提出的臨床開發策略，包括先進行隨機分組第二期 b（Phase 2b）劑量優化研究，再推進至以整體存活期（OS）為主要評估指標的確認性第三期（Phase 3）臨床試驗。
除胃癌外，HCB101 在大腸直腸癌（CRC）、頭頸部鱗狀細胞癌（HNSCC）及三陰性乳癌（TNBC）等癌症領域的初步臨床觀察，加上令人鼓舞的臨床前聯合治療研究結果，支持進一步探索 HCB101 與不同治療方式結合的可能性。
目前評估中的聯合治療策略包括腫瘤標靶抗體、抗體藥物複合體（ADC）、PD-1/VEGF 雙特異性抗體、治療性癌症疫苗，以及腫瘤微環境調節藥物等。
漢康生技相信，HCB101 的潛在價值不僅限於單一適應症，更有機會透過具科學驗證基礎的聯合治療策略及全球開發合作，建立更廣泛的免疫治療產品布局。
從科學創新邁向策略合作
漢康生技正推動以合作夥伴為核心的開發策略，結合 HCB101 的巨噬細胞導向作用機制與其他具互補性的治療技術。
近期與應世生物在局部黏著斑激酶（FAK）抑制領域，以及與 Aston Sci. 在治療性癌症疫苗領域展開的合作，展現公司持續拓展聯合治療開發策略的方向。
在本屆 BIO-Europe 大會期間，漢康生技計畫延續既有的科學交流，並探索新的潛在合作機會，涵蓋臨床前評估、臨床共同開發、藥物供應、聯合研究及策略授權等領域。
公司期望將具互補性的科學技術轉化為具體的開發計畫，並透過適當的實驗證據、臨床開發策略及合作夥伴共同投入的開發資源，推動相關計畫的實現。
FBDB™ 平台：將創新延伸至 HCB101 以外的產品管線
HCB101 為漢康生技自主開發的 Fc-Based Designer Biologics（FBDB™）平台奠定臨床基礎。該平台整合 Fc 蛋白工程與多功能分子設計技術，旨在同時作用於具互補性的免疫調控路徑。
公司持續擴展的產品管線包括：
- HCB303： 整合 SIRPα × PD-L1 × TIGIT 三重作用機制的三特異性免疫療法，已於 2026 年 10 月獲得美國 FDA IND 核准。
- HCB206： 針對 CD20 × SIRPα 的雙特異性候選藥物，開發方向涵蓋 B 細胞惡性腫瘤及自體免疫疾病。公司規劃在完成必要開發工作後，分別提交腫瘤及自體免疫適應症的 IND 申請。
- HCB301： 臨床階段的 SIRPα × PD-L1 × TGFβ 三特異性候選藥物，目前持續進行安全性及後續開發評估。
上述產品管線展現漢康生技在分子工程領域的廣泛技術能力，並為各項候選藥物的獨立開發及策略合作創造更多機會。
關於漢康生技
漢康生技（TWSE：7827）是一家全球臨床階段生技公司，透過自主開發的 FBDB™ 平台，致力於研發癌症及免疫介導疾病的下一代生物藥。憑藉多功能蛋白質工程技術，公司建立了包括 HCB101、HCB301 及 HCB303 在內的創新產品管線。漢康生技於台北、美國舊金山灣區及上海設有營運據點，致力於重新定義免疫治療，為全球病人開創新的治療可能性。
前瞻性聲明
本新聞稿包含有關漢康生技研究中候選藥物、臨床及法規開發計畫、潛在治療應用、未來合作機會、聯合治療策略及平台發展機會之前瞻性聲明。此類聲明涉及科學、臨床、法規、商業及營運等方面的風險與不確定性。初步臨床研究結果未必能預測後續對照試驗的結果，所提出的聯合治療策略或合作計畫亦未必能達成預期目標。除適用法律另有規定外，漢康生技不承擔更新前瞻性聲明的義務。